title: [Anti-angiogenic therapy in breast cancer].
abstract: Angiogenesis is important for tumor growth and breast cancer development. Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor(VEGF)-A, and it is the only anti-angiogenic agent approved for breast cancer treatment in Japan. In this article, we discuss the efficacy, tolerability, and potential future refinements for the use of bevacizumab.
authors.affiliation: Division of Breast and Medical Oncology, National Cancer Center Hospital.
authors.forename: Ryota
authors.initials: R
authors.lastname: Tanaka
authors.forename: Kenji
authors.initials: K
authors.lastname: Tamura
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D000068258:Bevacizumab; D001943:Breast Neoplasms / Q000098:blood supply / Q000188:drug therapy* / Q000473:pathology; D003131:Combined Modality Therapy; D006801:Humans; D009367:Neoplasm Staging; D042461:Vascular Endothelial Growth Factor A / Q000276:immunology
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab